US Patent

US9750684 — Ophthalmic formulations of cetirizine and methods of use

Formulation · Assigned to Nicox Ophthalmics Inc · Expires 2030-03-15 · 4y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects stable topical formulations of cetirizine hydrochloride for treating allergic conjunctivitis and/or allergic rhinoconjunctivitis.

USPTO Abstract

The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.

Drugs covered by this patent

Patent Metadata

Patent number
US9750684
Jurisdiction
US
Classification
Formulation
Expires
2030-03-15
Drug substance claim
No
Drug product claim
Yes
Assignee
Nicox Ophthalmics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.